01. Doctor Overview

Doctor Overview

As director of the mesothelioma program at the M.D. Anderson Cancer Center at the University of Texas in Houston, Anne Tsao M.D. is one of the nation’s foremost authorities on malignant mesothelioma.

Dr. Tsao and her colleagues at Anderson have penned many articles providing a large amount of information for many professional journals and have been involved in numerous clinical trials involving the treatment of malignant mesothelioma, an aggressive form of cancer that is often diagnosed in advanced stages and difficult to treat.

In articles in publications such as the Journal of Clinical Oncology, Tsao has discussed the impact of novel therapies, the importance of clinical trials, and controversial issues such as the use of extrapleural pneumonectomy in the treatment of the disease. She has also campaigned for the use of intrapleural therapies as well as gene therapy and immunotherapy for the treatment of malignant pleural mesothelioma and lectures nationally and internationally on these subjects.

Tsao has also performed studies involving smoking history and its impact on the prognosis of those with non-small cell lung cancers like mesothelioma. She has also stressed the need for chemo-prevention, the use of natural, synthetic, or biologic chemical agents to suppress cancer in high-risk populations or prevent carcinogenic progression to invasive cancer.

02. Fast Facts

Doctor Fast Facts

Main Speciality: Thoracic Medical Oncology

Other Interests & Specialties: Individualized cancer therapy, mesothelioma and lung cancer.

Certifications, Awards & Accolades: Co-Chair of the MDACC Clinical Research Committee, Scientific Advisory Committee member, chairing session participant for American Radium Society, Chair of the Communications Committee for International Association for the Study of Lung Cancer (IASLC), Chair of the Mesothelioma Applied Research Foundation (MARF), SWOG Executive Lung Committee member, SWOG Mesothelioma Steering Committee member, DSMB for NRG Thoracic Oncology member and NRG Lung Executive Committee member.

Education & Experience:

  • Internship and Residency at Indiana University
  • Medical Oncology Fellowship at the University of Texas MDACC
  • Medical Degree from the University of Chicago Pritzker School of Medicine
03. Publications


Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung CancerJournal of Clinical Oncology. September 2016. doi: 10.1200/JCO.2005.02.477

Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)BioMed Central Ltd. in Head & Neck Oncology. June 2010;2(1):15. doi: 10.1186/1758-3284-2-1-15

04. Mesothelioma Clinical Trials

Mesothelioma Clinical Trials by Anne S. Tsao, M.D.

Dr. Tsao is associated with the following clinical trials:

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Conditions: Mesothelioma, Lung Neoplasms

Last Updated: April 30, 2021

Status: Active, not recruiting

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Conditions: Mesothelioma

Last Updated: June 15, 2021

Status: Active, not recruiting

Dasatinib in Resectable Malignant Pleural Mesothelioma

Conditions: Mesothelioma

Last Updated: September 26, 2018

Status: Unknown status

Sorry, there are no clinical trials to display

Photo of Dr. Anne S. Tsao

Get Help Contacting Dr. Anne S. Tsao

Where Should We Overnight Your Free Guide?

    Privacy policy: All information is secure and will never be released